IIH
MCID: INT303
MIFTS: 56

Intracranial Hypertension, Idiopathic (IIH)

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Intracranial Hypertension, Idiopathic

MalaCards integrated aliases for Intracranial Hypertension, Idiopathic:

Name: Intracranial Hypertension, Idiopathic 56 52
Pseudotumor Cerebri 56 12 74 52 53 58 54 43 15 17 71
Benign Intracranial Hypertension 12 53 58 32
Idiopathic Intracranial Hypertension 12 52 58
Iih 52 58
Benign Intracran. Hypt. 12

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive


HPO:

31
intracranial hypertension, idiopathic:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Intracranial Hypertension, Idiopathic

NIH Rare Diseases : 52 Idiopathic intracranial hypertension (IIH) , formerly known as pseudotumor cerebri, is a condition that affects the brain. Pseudotumor cerebri literally translates to "false brain tumor ." This term was used because symptoms of IIH resemble those of brain tumors depsite no tumor being present. Symptoms of IIH may include severe headache, nausea and vomiting, altered vision, and pulsating sounds within the head. A person with IIH may also have symptoms such as a stiff neck, back or arm pain, eye pain, and memory problems. If the condition remains untreated, permanent visual loss or blindness may develop. While the exact underlying cause of IIH is not known (idiopathic), it is likely due to high fluid pressure within the skull that is due to buildup, or poor absorption, of cerebrospinal fluid (CSF). IIH most often (but not always) occurs in young, overweight, females. When symptoms of intracranial pressure have an identifiable cause such as another underlying disease or medication, the condition is instead referred to as secondary IH. Treatment for IIH may include medications called carbonic anhydrase inhibitors to control the production of CSF. In some cases, weight loss may also be recommended. However, medications and/or weight loss are not effective in all cases. In severe cases that do not respond to medication and weight loss, surgery may be needed to relieve symptoms and/or preserve vision.

MalaCards based summary : Intracranial Hypertension, Idiopathic, also known as pseudotumor cerebri, is related to empty sella syndrome and abducens nerve disease, and has symptoms including neurologic symptoms An important gene associated with Intracranial Hypertension, Idiopathic is SSTR1 (Somatostatin Receptor 1), and among its related pathways/superpathways are Relaxin signaling pathway and Peptide hormone metabolism. The drugs Isotretinoin and Lymecycline have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and eye, and related phenotypes are increased intracranial pressure and obesity

NINDS : 53 Pseudotumor cerebri literally means "false brain tumor." It is likely due to high pressure within the skull caused by the buildup or poor absorption of cerebrospinal fluid (CSF). The disorder is most common in women between the ages of 20 and 50. Symptoms of pseudotumor cerebri, which include headache, nausea, vomiting, and pulsating sounds within the head, closely mimic symptoms of large brain tumors.

Wikipedia : 74 Idiopathic intracranial hypertension (IIH), previously known as pseudotumor cerebri and benign... more...

More information from OMIM: 243200

Related Diseases for Intracranial Hypertension, Idiopathic

Diseases related to Intracranial Hypertension, Idiopathic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 566)
# Related Disease Score Top Affiliating Genes
1 empty sella syndrome 32.5 POMC IGF1 GH1
2 abducens nerve disease 30.8 POMC AQP4
3 communicating hydrocephalus 30.7 ASPRV1 AQP4 AQP1
4 obstructive hydrocephalus 30.4 CRLF1 AQP4 AQP1
5 hypercarotenemia and vitamin a deficiency, autosomal dominant 30.4 RBP4 RARA
6 traumatic brain injury 30.1 IGF1 GH1 AQP4
7 leptin deficiency or dysfunction 30.0 POMC LEP IGF1
8 superior semicircular canal dehiscence 29.9 CRLF1 ASPRV1
9 hyperprolactinemia 29.9 POMC IGF1 GH1
10 intracranial hypertension 29.8 SSTR1 SLC12A3 RBP4 F3 F2 AQP4
11 cerebral sinovenous thrombosis 29.8 F3 F2
12 papilledema 29.8 PCLO OGG1 F3 F2
13 branch retinal artery occlusion 29.8 F3 F2
14 migraine with or without aura 1 29.7 POMC OPN4 LEP F2
15 sleep disorder 29.6 POMC OPN4 LEP IGF1
16 amenorrhea 29.6 POMC LEP IGF1
17 pituitary apoplexy 29.6 POMC IGF1 GH1
18 pituitary tumors 29.6 POMC IGF1 GH1
19 intracranial sinus thrombosis 29.6 F3 F2
20 hyperthyroidism 29.5 POMC LEP IGF1 GH1
21 fibromyalgia 29.5 POMC LEP IGF1
22 hyperandrogenism 29.4 POMC IGF1 GH1
23 sagittal sinus thrombosis 29.4 F3 F2
24 turner syndrome 29.4 LEP IGF1 GH1
25 pituitary gland disease 29.4 SSTR1 POMC IGF1 GH1
26 pituitary adenoma, prolactin-secreting 29.4 SSTR1 POMC IGF1 GH1
27 insulin-like growth factor i 29.3 LEP IGF1 GH1
28 intracranial hypotension 29.3 OGG1 F3 F2 CRLF1
29 eating disorder 29.0 POMC LEP GH1
30 hypopituitarism 29.0 POMC LEP IGF1 GH1
31 polycystic ovary syndrome 28.9 POMC LEP IGF1 GH1
32 conn's syndrome 28.5 SLC12A3 POMC LEP IGF1 GH1
33 hypothyroidism 28.5 POMC LEP IGF1 GH1 F3 F2
34 congenital disorder of glycosylation, type iih 12.7
35 galactokinase deficiency 11.8
36 idiopathic infantile hypercalcemia 11.6
37 neurofibromatosis, type ii 10.5
38 acute promyelocytic leukemia 10.5
39 xeroderma pigmentosum, variant type 10.5
40 subependymoma 10.5 AQP4 AQP1
41 3-methylglutaconic aciduria, type iii 10.4
42 thrombosis 10.4
43 lupus erythematosus 10.4
44 dysferlinopathy 10.4 AQP4 AQP1
45 systemic lupus erythematosus 10.4
46 hypervitaminosis a 10.4
47 deficiency anemia 10.4
48 lyme disease 10.4
49 thrombophilia due to thrombin defect 10.3
50 hydrops, lactic acidosis, and sideroblastic anemia 10.3

Comorbidity relations with Intracranial Hypertension, Idiopathic via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential

Graphical network of the top 20 diseases related to Intracranial Hypertension, Idiopathic:



Diseases related to Intracranial Hypertension, Idiopathic

Symptoms & Phenotypes for Intracranial Hypertension, Idiopathic

Human phenotypes related to Intracranial Hypertension, Idiopathic:

58 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 increased intracranial pressure 58 31 hallmark (90%) Very frequent (99-80%) HP:0002516
2 obesity 58 31 frequent (33%) Frequent (79-30%) HP:0001513
3 papilledema 58 31 frequent (33%) Frequent (79-30%) HP:0001085
4 allergy 58 31 frequent (33%) Frequent (79-30%) HP:0012393
5 sleep disturbance 58 31 occasional (7.5%) Occasional (29-5%) HP:0002360
6 diplopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000651
7 photophobia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000613
8 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
9 visual loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0000572
10 blurred vision 58 31 occasional (7.5%) Occasional (29-5%) HP:0000622
11 abnormal emotion/affect behavior 58 31 occasional (7.5%) Occasional (29-5%) HP:0100851
12 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
13 scintillating scotoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0010822
14 depressivity 58 31 very rare (1%) Very rare (<4-1%) HP:0000716
15 back pain 58 31 very rare (1%) Very rare (<4-1%) HP:0003418
16 migraine 58 31 very rare (1%) Very rare (<4-1%) HP:0002076
17 vertigo 58 31 very rare (1%) Very rare (<4-1%) HP:0002321
18 lethargy 58 31 very rare (1%) Very rare (<4-1%) HP:0001254
19 olfactory auras 58 31 very rare (1%) Very rare (<4-1%) HP:0011161
20 pulsatile tinnitus 58 31 very rare (1%) Very rare (<4-1%) HP:0008629
21 hypertension 31 HP:0000822
22 headache 58 Very frequent (99-80%)

Symptoms via clinical synopsis from OMIM:

56
H E E N T:
papilledema
pseudotumor cerebri
idiopathic intracranial hypertension

Clinical features from OMIM:

243200

UMLS symptoms related to Intracranial Hypertension, Idiopathic:


neurologic symptoms

GenomeRNAi Phenotypes related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

26 (show top 50) (show all 54)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.36 POMC GH1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.36 POMC IGF1 PCLO RBP4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.36 RARA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.36 ALG6
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.36 LEP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.36 IGF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.36 GH1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.36 ALG6 RARA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.36 PCLO F2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.36 F2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.36 ALG6 F3 LEP POMC
12 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.36 F3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.36 RBP4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.36 F2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.36 GH1 SSTR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.36 ALG6 IGF1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-144 10.36 IGF1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.36 F2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.36 GH1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.36 SSTR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.36 ALG6 IGF1 F2 GH1 RARA SSTR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.36 F3 IGF1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.36 IGF1 PCLO
24 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.36 PCLO
25 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.36 ALG6
26 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.36 IGF1 F2 SSTR1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.36 SSTR1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.36 RARA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.36 ALG6
30 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.36 SSTR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.36 LEP RBP4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.36 IGF1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.36 IGF1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.36 IGF1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.36 ALG6
36 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.36 PCLO GH1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.36 POMC IGF1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.36 POMC
39 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.36 RARA
40 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.36 ALG6
41 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.36 F2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.36 GH1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.36 GH1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.36 PCLO SSTR1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.36 F3 SSTR1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.36 F2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.36 F3
48 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.36 ALG6
49 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.36 POMC
50 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.36 POMC

MGI Mouse Phenotypes related to Intracranial Hypertension, Idiopathic:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 AQP1 AQP4 F2 F3 IGF1 LEP
2 behavior/neurological MP:0005386 10.17 AQP1 AQP4 CRLF1 F2 F3 LEP
3 cardiovascular system MP:0005385 10.14 AQP1 AQP4 F2 F3 IGF1 IHH
4 mortality/aging MP:0010768 10.13 ALG6 AQP1 AQP4 CRLF1 F2 F3
5 nervous system MP:0003631 10.1 AQP1 AQP4 CRLF1 F2 F3 IGF1
6 renal/urinary system MP:0005367 9.81 ALG6 AQP1 AQP4 IGF1 LEP POMC
7 respiratory system MP:0005388 9.56 AQP1 AQP4 F2 F3 IGF1 IHH
8 vision/eye MP:0005391 9.28 AQP1 AQP4 F3 IHH LEP OPN4

Drugs & Therapeutics for Intracranial Hypertension, Idiopathic

Drugs for Intracranial Hypertension, Idiopathic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
2
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
3
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
4 Natriuretic Agents Phase 4
5 Anticonvulsants Phase 4
6 Carbonic Anhydrase Inhibitors Phase 4
7 diuretics Phase 4
8
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
9
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
10
Amphetamine Approved, Illicit, Investigational Phase 3 300-62-9 5826 3007
11
Aspirin Approved, Vet_approved Phase 2, Phase 3 50-78-2 2244
12
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
13
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
14
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
15
Naproxen Approved, Vet_approved Phase 2, Phase 3 22204-53-1 1302 156391
16
Codeine Approved, Illicit Phase 2, Phase 3 76-57-3 5284371
17
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
18
Arsenic trioxide Approved, Investigational Phase 3 1327-53-3 518740
19
Idarubicin Approved Phase 3 58957-92-9 42890
20
leucovorin Approved Phase 3 58-05-9 6006 143
21
Mercaptopurine Approved Phase 3 50-44-2 667490
22
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
23
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
25
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
26 Neurotransmitter Agents Phase 3
27 Sympathomimetics Phase 3
28 Dopamine Uptake Inhibitors Phase 3
29 Central Nervous System Stimulants Phase 3
30 Dopamine Agents Phase 3
31 Autonomic Agents Phase 3
32 Adrenergic Agents Phase 3
33 Vitamin B Complex Phase 3
34 Vitamin B9 Phase 3
35 Folate Phase 3
36 Dermatologic Agents Phase 3
37 Antibiotics, Antitubercular Phase 3
38 Anti-Bacterial Agents Phase 3
39 Central Nervous System Depressants Phase 2, Phase 3
40 Fibrinolytic Agents Phase 2, Phase 3
41 Anti-Inflammatory Agents Phase 2, Phase 3
42 Narcotics Phase 2, Phase 3
43 Analgesics, Non-Narcotic Phase 2, Phase 3
44 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
45 Respiratory System Agents Phase 2, Phase 3
46 Platelet Aggregation Inhibitors Phase 2, Phase 3
47 Cyclooxygenase Inhibitors Phase 2, Phase 3
48 Antipyretics Phase 2, Phase 3
49 Analgesics, Opioid Phase 2, Phase 3
50 Antitussive Agents Phase 2, Phase 3

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment Unknown status NCT02149615 Phase 4
2 A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair Unknown status NCT01889498 Phase 4 Acetazolamide
3 Accuracy of ShuntCheck and MRI in Detection of Shunt Obstruction in Patients Receiving Shunt Patency Test Withdrawn NCT00793416 Phase 4
4 An Open-label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence (COATS) Unknown status NCT02541500 Phase 3 Minocycline
5 A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
6 Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation Completed NCT00866918 Phase 3 arsenic trioxide;mitoxantrone hydrochloride;idarubicin;tretinoin;cytarabine;mercaptopurine tablet;methotrexate
7 Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss Active, not recruiting NCT03501966 Phase 3 Acetazolamide
8 Normal Pressure Hydrocephalus Treatment by Acetazolamide Terminated NCT02163330 Phase 3 Acetazolamide;sugar pill
9 Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study. Completed NCT02017444 Phase 2 AZD4017
10 A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris Completed NCT02815332 Phase 2 BPX-01 1% Minocycline Topical Gel;BPX-01 2% Minocycline Topical Gel;BPX-01 Vehicle Topical Gel
11 Evaluation of Effect of Doxycycline Verses Placebo on Diabetic Retinopathy Progression and Retinal Function in Patients With Severe Non-proliferative or Mild or Moderate (Non-high-risk) Proliferative Diabetic Retinopathy Completed NCT00511875 Phase 2 doxycycline monohydrate;placebo
12 The Effect of Single-dose Propofol Injection on Pain and Quality of Life in Chronic Daily Headache: a Randomized Double-blind Controlled Trial Completed NCT00228267 Phase 2 Propofol
13 Acetazolamide for Treating NPH in Shunt-candidates Patients: an Open Label Feasibility Trial Recruiting NCT03779594 Phase 2 Acetazolamide
14 A Proof-of-concept Study to Assess the Effect of Recombinant Human Growth Hormone on the Size of the Replication-competent Viral Reservoir in HIV-infected Individuals on Suppressive Antiretroviral Therapy Recruiting NCT03091374 Phase 2 Somatotropin (Human)
15 PRISM: A Double Blind, Randomized, Vehicle Controlled Phase 2 Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in the Treatment of Inflammatory Lesions of Papulopustular Rosacea Active, not recruiting NCT03667222 Phase 2 minocycline topical gel;topical gel vehicle
16 Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy Active, not recruiting NCT01407809 Phase 1
17 Evaluation of the Feasibility, Safety and Efficacy of Venous Stenting for Internal Jugular Vein Stenosis Not yet recruiting NCT03373292 Phase 1
18 OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension Unknown status NCT02665858
19 Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension Unknown status NCT02394067
20 Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension Unknown status NCT02143258
21 Correlation Between Intracranial Pressure as Measured by Lumbar Puncture Manometry and Percentage Body Fat as Measured by Air-displacement Plethysmography Unknown status NCT03144297
22 Tablet-guided Versus Freehand (Tab-Guide) Ventriculostomy : Study Protocol to the Test Accuracy of Ventriculostomy in a Randomized Controlled Trial Unknown status NCT02048553
23 D-dimer and the Use of Anticoagulation in IIH Completed NCT03963336 Early Phase 1 LMWH;acetazolamide
24 Prospective Measurement of Blood Pressure and End Tidal Carbon Dioxide Content Effects on Venous Sinus Caliber and Pressures in Patients With Idiopathic Intracranial Hypertension Undergoing Stenting Completed NCT03867461
25 The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study Completed NCT00071903
26 Comparison of Continuous Noninvasive and Invasive Intracranial Pressure Measurement--Celda Infusion Subprotocol Completed NCT01976559
27 High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM Completed NCT00388921 Vitamin A
28 Effect of Preoperative Hospitalization Duration on Post-operative Cognitive Dysfunction in Patients Who Underwent Hip Surgery Under Regional Anesthesia Completed NCT03290599
29 Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension Recruiting NCT04032379
30 Evaluating Raised Intracranial Pressure Using MR Elastography Recruiting NCT03096743
31 Assessment of Pupillary Response and Visual Field Defects by Objective Multifocal Chromatic Pupillometer in Patients With Pseudotumor Cerebri and Healthy Subjects Recruiting NCT03304314
32 Clinical Evaluation of the Serenity River Stent System to Treat Idiopathic Intracranial Hypertension Recruiting NCT03556085
33 Astronaut Vision Issues and One Carbon Metabolism: Expanded Polymorphism Evaluation and Evaluation in a Potential Analog Population Recruiting NCT02896452
34 Ocular and Vision Problems in Patients After Fontan Operation Recruiting NCT03170778
35 A Randomized Clinical Trial on the Efficacy and Cost-efficacy of Adding on a Mindfulness-based Therapy to Standard Medical Prophylaxis in the Treatment of Patients With Chronic Migraine Associated to Medication Overuse Following Structured Withdrawal: the Mind-CM Study Recruiting NCT03671681 Prophylactic
36 A Randomised Controlled Trial of Bariatric Surgery Versus a Community Weight Loss Programme for the Sustained Treatment of Idiopathic Intracranial Hypertension: the IIH:WT Trial Active, not recruiting NCT02124486
37 Assessment of Venous Drainage in Idiopathic Intracranial Hypertension Not yet recruiting NCT04115553
38 Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial (OPEN-UP) Not yet recruiting NCT02513914
39 Venous Sinus Pressures in Normal Individuals Not yet recruiting NCT03948971
40 The Potential Value of Axial Length and Central Corneal Thickness in the Assessment for Risk of Permanent Optic Nerve Damage and Visual Field Loss in Benign Intracranial Hypertension Terminated NCT02541994
41 Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement: Continuous Intracranial Pressure Monitoring Subprotocol Terminated NCT01863381
42 Pilot Study of Acetazolamide to Prevent Post Operative Cerebrospinal Fluid (CSF) Leak in Patients Undergoing Endoscopic Skull Base Surgery Withdrawn NCT02902133 Acetazolamide
43 Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834
44 Analysis of Translaminar Pressure Gradient Using Noninvasive Cerebrospinal Fluid Pressure Monitoring Withdrawn NCT02828891

Search NIH Clinical Center for Intracranial Hypertension, Idiopathic

Cochrane evidence based reviews: pseudotumor cerebri

Genetic Tests for Intracranial Hypertension, Idiopathic

Anatomical Context for Intracranial Hypertension, Idiopathic

MalaCards organs/tissues related to Intracranial Hypertension, Idiopathic:

40
Brain, Pituitary, Eye, Kidney, Testes, Heart, Liver

Publications for Intracranial Hypertension, Idiopathic

Articles related to Intracranial Hypertension, Idiopathic:

(show top 50) (show all 1321)
# Title Authors PMID Year
1
Expression of somatostatin receptors 1 and 2 in human choroid plexus and arachnoid granulations: implications for idiopathic intracranial hypertension. 54 56
12427069 2002
2
A familial coincidence of pseudotumor cerebri and communicating hydrocephalus. 61 56
1876253 1991
3
Pseudotumor cerebri. Report of a familial occurrence. 61 56
4808492 1974
4
Vitamin A in the cerebrospinal fluid of patients with and without idiopathic intracranial hypertension. 56
12402264 2002
5
Familial benign intracranial hypertension. 56
932759 1976
6
Papilledema and idiopathic intracranial hypertension. 56
5775633 1969
7
Vitamin B12 Deficiency: An Association or Etiology of Pseudotumor Cerebri in An Infant. 61
32036594 2020
8
Pseudotumor Cerebri Syndrome: From Childhood to Adulthood Risk Factors and Clinical Presentation. 61
31928127 2020
9
Neurenteric cyst secondary to lumboperitoneal shunt. 61
32038886 2020
10
Clinical performance of fixed-pressure Sphera Duo® hydrocephalus shunt. 61
32022117 2020
11
A rare case of pseudotumor cerebri in adult Lyme disease. 61
31998499 2020
12
Cerebrospinal fluid dynamics in pediatric pseudotumor cerebri syndrome. 61
31325030 2020
13
Long-Term Follow-up of Pseudotumor Cerebri Syndrome in Prepubertal Children, Adolescents, and Adults. 61
31604646 2019
14
Pseudotumor cerebri in a transgender woman: case report and literature review. 61
31879065 2019
15
Men Are from Mars, Idiopathic Intracranial Hypertension Is from Venous: The Role of Venous Sinus Stenosis and Stenting in Idiopathic Intracranial Hypertension. 61
31847040 2019
16
Do Most Patients With a Spontaneous Cerebrospinal Fluid Leak Have Idiopathic Intracranial Hypertension? 61
30747786 2019
17
Infantile Idiopathic Intracranial Hypertension: A Case Study and Review of the Literature. 61
31309848 2019
18
[What's New in Papilloedema, Pseudotumor Cerebri and Idiopathic Intracranial Hypertension]. 61
31600818 2019
19
Coprescription of Isotretinoin and Tetracyclines for Acne is Rare: An Analysis of the National Ambulatory Medical Care Survey. 61
32038749 2019
20
Magnetic Resonance Imaging Findings in Pediatric Pseudotumor Cerebri Syndrome. 61
31303369 2019
21
Fulminant Pseudotumor Cerebri Syndrome Secondary to Over-the-Counter Topical Retinoids. 61
31609833 2019
22
Magnetic Resonance Imaging Findings of All-Trans Retinoic Acid-induced Pseudotumor Cerebri in a Child With Acute Promyelocytic Leukemia. 61
31593006 2019
23
Dural venous sinus stenting as a stand-alone treatment for spontaneous skull base CSF leak secondary to venous pseudotumor cerebri syndrome. 61
31352494 2019
24
Contemporary management of the pseudotumor cerebri syndrome. 61
31478394 2019
25
Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. 61
31475868 2019
26
Mechanical Thrombectomy and Thrombolysis for Dural Venous Sinus Thrombosis. 61
31226455 2019
27
CASE REPORT OF THE ROLE OF OPTICAL COHERENCE TOMOGRAPHY IN RECOMBINANT GROWTH HORMONE THERAPY. 61
31568222 2019
28
Association between cycline antibiotic and development of pseudotumor cerebri syndrome. 61
30905802 2019
29
Quetiapine-Associated Pseudotumor Cerebri. 61
31356344 2019
30
Pseudotumor Cerebri Syndrome in Children. 61
31292773 2019
31
Response to Correspondence "In Pseudotumor cerebri, hormonal contraception is not associated, and the diagnosis remains as 'Idiopathic Intracranial Hypertension'". 61
31130218 2019
32
In Pseudotumor Cerebri, Hormonal Contraception is Not Associated, and the Diagnosis Remains Idiopathic Intracranial Hypertension. 61
31014540 2019
33
A case of bilateral fourth nerve palsy associated with pseudotumor cerebri syndrome. 61
31038553 2019
34
Mastoid osteoma with stenosis of transverse and sigmoid sinuses as a cause of pseudotumor cerebri. 61
31262987 2019
35
Pseudotumor cerebri induced by topical application of steroid: a case report. 61
31274035 2019
36
[A Case of Meningitis Caused by Globicatella sanguinis in a Patient with a Lumbo-peritoneal Shunt]. 61
31414636 2019
37
Demographics, clinical features, and response to conventional treatments in pediatric Pseudotumor Cerebri syndrome: a single-center experience. 61
31025099 2019
38
The Occipital Emissary Vein: A Possible Marker for Pseudotumor Cerebri. 61
31072972 2019
39
From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM. 61
30937698 2019
40
Spinal CSF flow in response to forced thoracic and abdominal respiration. 61
30947716 2019
41
Idiopathic intracranial hypertension presenting with isolated unilateral facial nerve palsy: a case report. 61
30999940 2019
42
The Significance and Reliability of Imaging Findings in Pseudotumor Cerebri. 61
31312231 2019
43
Epidural Blood Patch for Postdural Puncture Headache due to Lumboperitoneal Shunt Placement in a Patient With Pseudotumor Cerebri: A Case Report. 61
30272589 2019
44
Optic nerve sheath fenestration: a revised lateral approach for nerve access. 61
29565728 2019
45
Nuances of Endovascular Treatment of Transverse/Sigmoid Sinus Stenosis With Stenting Venoplasty in a Patient With Pseudotumor Cerebri: 2-Dimensional Operative Video. 61
30060093 2019
46
Methotrexate-induced pseudotumor cerebri in a patient with juvenile idiopathic arthritis. 61
30083940 2019
47
RE: "An Estimation of the Risk of Pseudotumor Cerebri Among Users of the Levonorgestrel Intrauterine Device". 61
30723528 2019
48
Prognostic value of JAK2V617F mutation in pseudotumor cerebri associated with cerebral venous sinus thrombosis. 61
30251405 2019
49
Non-Syndromic Craniosynostosis Mimicking Primary Pseudotumor Cerebri Syndrome. 61
30474204 2019
50
Acute aseptic meningitis during isotretinoin treatment for nodular acne solely presenting with headache: case report and brief review of the literature. 61
30160569 2019

Variations for Intracranial Hypertension, Idiopathic

Expression for Intracranial Hypertension, Idiopathic

Search GEO for disease gene expression data for Intracranial Hypertension, Idiopathic.

Pathways for Intracranial Hypertension, Idiopathic

Pathways related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.95 SSTR1 RARA POMC IGF1 GH1
2
Show member pathways
11.72 POMC LEP IGF1 GH1
3 11.25 IHH IGF1 GH1
4 11.04 RARA LEP IGF1 GH1

GO Terms for Intracranial Hypertension, Idiopathic

Cellular components related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 RBP4 POMC LEP IHH IGF1 GH1
2 extracellular region GO:0005576 9.36 RBP4 PRELP POMC LEP IHH IGF1

Biological processes related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 RARA OGG1 LEP IHH IGF1 AQP1
2 positive regulation of cell proliferation GO:0008284 9.85 RARA LEP IHH IGF1 F2 CRLF1
3 cellular response to retinoic acid GO:0071300 9.65 RARA LEP AQP1
4 negative regulation of tumor necrosis factor production GO:0032720 9.63 RARA POMC IGF1
5 response to ethanol GO:0045471 9.62 RBP4 RARA OGG1 LEP
6 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.52 IGF1 GH1
7 negative regulation of cartilage development GO:0061037 9.51 RARA LEP
8 multicellular organismal water homeostasis GO:0050891 9.49 AQP4 AQP1
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.46 LEP IGF1 GH1 F2
10 bone mineralization involved in bone maturation GO:0035630 9.43 LEP IGF1
11 positive regulation of JAK-STAT cascade GO:0046427 9.43 LEP GH1 F2
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.26 LEP IGF1 GH1 CRLF1
13 response to estradiol GO:0032355 9.02 RARA OGG1 LEP IHH GH1

Molecular functions related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 water channel activity GO:0015250 8.96 AQP4 AQP1
2 hormone activity GO:0005179 8.92 POMC LEP IGF1 GH1

Sources for Intracranial Hypertension, Idiopathic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....